Search results
Results from the WOW.Com Content Network
An analyst initiated coverage of Emergent BioSolutions (NYSE: EBS) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled ...
Emergent BioSolutions (NYSE: EBS) saw its shares tumble on Tuesday, due to news of a share sell-off. The selling parties are mainly entities affiliated with OHA Agency, a business that provided a ...
Tuesday, Emergent BioSolutions Inc. (NYSE:EBS) received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States ...
(Reuters) -The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions' smallpox vaccine for use in people at high risk of mpox infection. The FDA clearance, announced ...
Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q3 2024 Earnings Call Nov 06, 2024, 5:00 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
(Reuters) - Drugmaker Emergent BioSolutions said on Monday that it would reduce its workforce in Lansing, Michigan, by up to 70 roles as part of its ongoing restructuring efforts.
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. [2] It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -2,016.67% and 10.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for ...